Active specific immunotherapy with tumor cells andCorynebacterium parvum. A phase I study
- 1 May 1979
- Vol. 43 (5) , 1619-1623
- https://doi.org/10.1002/1097-0142(197905)43:5<1619::aid-cncr2820430509>3.0.co;2-o
Abstract
Autologous, irradiated (10,000 rads) tumor cells mixed with C. parvum were given as weekly intracutaneous injections to fifteen patients with residual malignant disease. The toxicity was minimal and distinctly less than has been seen with tumor cell‐BCG immunotherapy. A goal of 4 injections of 107 cells each was possible in only 4 patients because of limitations in methods of disaggregation and quantity of tumor available. The feasibility aspects are discussed and a case report of a prolonged regression is presented.This publication has 12 references indexed in Scilit:
- A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanomaCancer, 1977
- Controlled trial of active immunotherapy in management of stage IIB malignant melanoma.BMJ, 1977
- ACTIVE SPECIFIC IMMUNOTHERAPY FOR OVARIAN CANCERThe Lancet, 1976
- Feasibility study of active immunotherapy in patients with solid tumorsCancer, 1976
- Active specific immunotherapy of mouse methylcholanthrene induced tumours with Corynebacterium parvum and irradiated tumour cellsBritish Journal of Cancer, 1975
- Potentiation of the Tumor-Specific Immune Response by Corynebacterium parvum 2JNCI Journal of the National Cancer Institute, 1975
- Immunopotentiation With BeG: Dimensions of a Specific Antitumor Response2JNCI Journal of the National Cancer Institute, 1975
- Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot studyBritish Journal of Cancer, 1975
- Active specific immunization in malignant melanomaMedical and Pediatric Oncology, 1975
- A Method for Dinitrochlorobenzene Contact SensitizationNew England Journal of Medicine, 1972